{"id":245124,"date":"2026-10-09T09:03:42","date_gmt":"2026-10-09T14:03:42","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/10\/radioimmunotherapy-rit-in-aml-transplant-conditioning-can-radiation-be-targeted-to-leukemia"},"modified":"2026-10-09T09:03:42","modified_gmt":"2026-10-09T14:03:42","slug":"radioimmunotherapy-rit-in-aml-transplant-conditioning-can-radiation-be-targeted-to-leukemia","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/10\/radioimmunotherapy-rit-in-aml-transplant-conditioning-can-radiation-be-targeted-to-leukemia","title":{"rendered":"Radioimmunotherapy (RIT) in AML Transplant Conditioning: Can Radiation Be Targeted to Leukemia?"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/radioimmunotherapy-rit-in-aml-transplant-conditioning-can-radiation-be-targeted-to-leukemia.jpg\"><\/a><\/p>\n<p>Reduced-intensity conditioning (RIC) has made allogeneic hematopoietic cell transplantation (allo-HCT) accessible to older patients and those who can\u2019t tolerate myeloablative conditioning. The trade-off is less pre-transplant cytoreduction, and relapse remains a major limitation, especially in acute myeloid leukemia with adverse molecular or cytogenetic features and in patients who are MRD-positive at transplant.<\/p>\n<p>Radioimmunotherapy (RIT) is being explored as a way to intensify leukemia-directed radiation without proportionally increasing radiation exposure to nonhematopoietic organs. A monoclonal antibody recognizes an antigen expressed in the hematopoietic compartment and carries a therapeutic radionuclide to the marrow, spleen and other sites of disease. It can be incorporated into an RIC transplant regimen.<\/p>\n<p>The biological rationale, clinical experience, and emerging \u03b1-emitter platforms are reviewed in<a href=\"https:\/\/www.frontiersin.org\/journals\/oncology\/articles\/10.3389\/fonc.2026.1846420\/full\" target=\"_blank\" rel=\"noopener\"> Frontiers<\/a>. The clinical evidence remains early phase, but it shows that substantial radiation doses can be concentrated in hematopoietic tissues with reliable donor engraftment.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Reduced-intensity conditioning (RIC) has made allogeneic hematopoietic cell transplantation (allo-HCT) accessible to older patients and those who can\u2019t tolerate myeloablative conditioning. The trade-off is less pre-transplant cytoreduction, and relapse remains a major limitation, especially in acute myeloid leukemia with adverse molecular or cytogenetic features and in patients who are MRD-positive at transplant. Radioimmunotherapy (RIT) is [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,412],"tags":[],"class_list":["post-245124","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-genetics"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/245124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=245124"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/245124\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=245124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=245124"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=245124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}